Connect Biopharma Conference Call Summary Company Overview - **Company**: Connect Biopharma (NasdaqGM:CNTB) - **Focus**: Development of Rademikibart, an IL-4 receptor alpha monoclonal antibody for asthma, COPD, and atopic dermatitis Key Updates on Rademikibart Clinical Development - **Rademikibart** is designed for treating acute exacerbations of asthma and COPD, with a focus on rapid onset of action and improved efficacy compared to existing treatments like dupilumab [4][25] - Preliminary results from an IV clinical pharmacology study show significant improvements in FEV1 (Forced Expiratory Volume in 1 second) within 15-30 minutes, with increases of 200-400 mL observed [20][24] - The drug demonstrates a faster onset of action, with significant improvements noted as early as 15 minutes post-administration [18][21] Mechanism of Action - Rademikibart shows a unique binding orientation and greater internalization compared to dupilumab, leading to a reduction in eosinophils, which is contrary to the increase seen with dupilumab [5][42] - The drug enhances the efficacy of beta-agonists, improving bronchodilation, which is not observed with other biologics [10][77] Safety Profile - The IV administration of Rademikibart has shown a clean safety profile with no significant adverse events reported in the small study [25][26] Market Opportunity - There are over 1 million emergency department visits for asthma and 1.3 million for COPD patients due to acute exacerbations, indicating a significant unmet need in the market [12] - Current biologics are not approved for acute exacerbations, presenting a unique opportunity for Rademikibart to fill this gap [25] Financial Outlook - Connect Biopharma has cash equivalents of $55 million, expected to cover operations into the second half of 2027 [44] - A worldwide peak sales forecast of approximately $5 billion for both acute and chronic indications in asthma and COPD has been projected [32] Upcoming Milestones - Results from two phase II acute asthma and COPD studies are anticipated mid-year [44] - A pending New Drug Application in China for atopic dermatitis is expected to be approved between mid-year and the end of the year [44] Atopic Dermatitis Data - In a study sponsored by Simcere Pharmaceutical, Rademikibart showed an 87.1% response rate at 52 weeks and a 96.6% response rate for EASI-75, indicating strong efficacy [35][36] - The drug has a significantly lower rate of conjunctivitis compared to dupilumab, enhancing its safety profile [37] Conclusion - Connect Biopharma is positioned to leverage the unique properties of Rademikibart to address significant unmet needs in the treatment of asthma, COPD, and atopic dermatitis, with promising clinical data and a strong market opportunity ahead [43][44]

Summary of Connect Biopharma Holdings (CNTB) Conference Call Company Overview - Connect Biopharma Holdings (CNTB) is undergoing a transformation referred to as "Connect 2.0" with a new management team focused on drug development and regulatory activities [3][4] - The lead program is retimicobart, a next-generation IL-4 receptor alpha monoclonal antibody, positioned as a second-generation alternative to Dupixent [3][4] Core Product Insights - Retimicobart shows a significant improvement in FEV1, a key measure of airway function, with one of the largest improvements seen in biologics for asthma trials [4][5] - The onset of effect occurs within 24 hours, allowing for evaluation in acute settings rather than traditional chronic studies [5][6] - There are over 1 million asthma and 1.3 million COPD patients visiting ERs annually due to acute exacerbations, indicating a substantial market opportunity [5][9] Market Opportunity - Current biologics do not have indications for acute exacerbations, creating a "white space" for retimicobart [6][22] - Market research indicates that the novel acute indication could drive significant chronic use, with a preference share of 40%-45% for acute use and 75% for chronic treatment following acute administration [10][22] - The product is expected to have a multi-billion dollar commercial potential with both acute and chronic indications [23][30] Clinical Development - Two parallel trials (cbreeze stat) for asthma and COPD are underway, with data expected in the first half of the following year [15][16] - The acute studies are designed to assess improvements in FEV1 and reduce hospitalization rates, with a focus on cost savings for hospitals [16][30] - The company has received FDA clearance to move into phase three for atopic dermatitis, pending completion of a partner study in China [21][24] Financial Considerations - Development costs for acute indications are estimated at around $50 million, while combined acute and chronic programs could reach $200 million [29] - The company has sufficient cash reserves to execute its plans into 2027, allowing for strategic development without immediate dilution [24][30] Regulatory Landscape - There is no precedent for acute indications in the biologics market, presenting both challenges and opportunities for Connect Biopharma [33] - Extensive discussions with the FDA have provided insights into potential pathways for approval [33] Conclusion - Connect Biopharma is positioned to leverage its innovative product retimicobart in a largely untapped market for acute asthma and COPD treatment, with a strong focus on rapid clinical development and strategic partnerships to enhance its market presence [22][30]